Details:

• Personal Author:
  Cortese, Margaret M. ; Parashar, Umesh D.

  Cortese, Margaret M. ; Parashar, Umesh D. Less -
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.

  United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. Less -
• Description:
  "Rotavirus is the most common cause of severe gastroenteritis in infants and young children worldwide. Before initiation of the rotavirus vaccination program in the United States in 2006, approximately 80% of U.S. children had rotavirus gastroenteritis by age 5 years. Each year during the 1990s and early 2000s, rotavirus resulted in approximately 410,000 physician visits, 205,000272,000 emergency department visits, and 55,00070,000 hospitalizations among U.S. infants and children, with total annual direct and indirect costs of approximately $1 billion. In February 2006, a live, oral, human-bovine reassortant rotavirus vaccine (RotaTeq® [RV5]) was licensed as a 3-dose series for use among U.S. infants for the prevention of rotavirus gastroenteritis, and the Advisory Committee on Immunization Practices (ACIP) recommended routine use of RV5 among U.S. infants (CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2006;55[No. RR-12]). In April 2008, a live, oral, human attenuated rotavirus vaccine (Rotarix® [RV1]) was licensed as a 2-dose series for use among U.S. infants, and in June 2008, ACIP updated its rotavirus vaccine recommendations to include use of RV1. This report updates and replaces the 2006 ACIP statement for prevention of rotavirus gastroenteritis. ACIP recommends routine vaccination of U.S. infants with rotavirus vaccine. RV5 and RV1 differ in composition and schedule of administration. RV5 is to be administered orally in a 3-dose series, with doses administered at ages 2, 4, and 6 months. RV1 is to be administered orally in a 2-dose series, with doses administered at ages 2 and 4 months. ACIP does not express a preference for either RV5 or RV1. The recommendations in this report also address the maximum ages for doses, contraindications, precautions, and special situations for the administration of rotavirus vaccine." - p. 1
• Content Notes:
  prepared by Margaret M. Cortese, Umesh D. Parashar, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases.
  
  Includes bibliographical references (p. 21-24).
  
  
• Subjects:
  [+]

  Diarrhea, Infantile Gastroenteritis Immunization Schedule Rotavirus Infections Rotavirus Vaccines Vaccines, Attenuated
• Source:
  MMWR. Recommendations and Reports 2009; v. 58, no. 2
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print);1545-8601 (digital);
• Pubmed ID:
  19194371
• Document Type:
  Journal Issue
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  print; 25 p. : ill. ; 28 cm.
• Volume:
  58
• Issue:
  2
• Collection(s):
  Advisory Committee on Immunization Practices (ACIP) Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  [+]

  urn:sha-512:6906ff571e5824ff678a9f9d579f4c86696a3b6cb6bb35cb5e34dd7aa62980c4ef83c50e54cc979aac80b5fa6b1b87e37cc0a2217fc2c7da0d2f61a274aa37da
• Download URL:
  https://stacks.cdc.gov/view/cdc/5189/cdc_5189_DS1.pdf
• File Type:
  [PDF-22.70 MB]